Jun 15, 2021 12:53 Source: BSE
Biofil Chemicals and Pharmaceuticals - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received the intimation letter from our Registrars and Share Transfer Agent - Ankit Consultancy Private Limited (enclosed herewith), providing information regarding the duplicate share certificates that have been issued
Apr 30, 2021 13:12 Source: BSE
Biofil Chemicals and Pharmaceuticals - CLARIFICATION ON PRICE MOVEMENT
With reference to your Email L/SURV/ONL/PV/NP/ 2021-2022 / 133 dated 30th April, 2021 in relation to significant movement in price of Equity Shares of our company listed on your good Exchange. We hereby confirm and ensure that there are no material development/event occurring in our company which will have significant impact on prices of Equity Shares of our company.
Apr 30, 2021 11:26 Source: BSE
Biofil Chemicals and Pharmaceuticals - Clarification sought from Biofil Chemicals & Pharmaceuticals Ltd
The Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Ltd on April 30, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
Apr 29, 2021 16:59 Source: BSE
Biofil Chemicals and Pharmaceuticals - Filing Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half Year Ended 31St March, 2021
In compliance with Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/48 dated 26th March, 2020 please find enclosed the certificate obtained from Practicing Company Secretary for the half year ended 31st March, 2021 for your reference and records. Please find the same in order and oblige.
Apr 23, 2021 16:11 Source: BSE
Biofil Chemicals and Pharmaceuticals - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
|Sr. No. ||Particulars ||Details |
|1||Name of Compay||BIOFIL CHEMICALS & PHARMACEUTICALS LTD.|
|3 ||Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) ||0.00|
|4||Highest Credit Rating during the previous FY ||NA|
|4a||Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)||Not Applicable|
|5||Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework||BSE|
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No
Name of the Company Secretary: SHIKHA KHILWANI
Designation: COMPANY SECRETARY COMPLIANCE OFFICER
Name of the Chief Financial Officer: JITENDRA KUMAR SAHU
Designation: Chief Financial Officer
Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Apr 23, 2021 15:40 Source: BSE
Biofil Chemicals and Pharmaceuticals - Announcement under Regulation 30 (LODR)-Demise
We regret to inform you of the sudden and sad demise of Mr. Subhash Chandra Swarnakar (DIN: 01658151), Non-Executive Independent Director of the Company, on Thursday, 15th April, 2021.